CD22 - Revision history

John at 19:39, 4 July 2023

2023-07-04T19:39:38Z

← Older revision		Revision as of 21:39, 4 July 2023
Line 67:		Line 67:
	\|-		\|-
	!colspan="8"\|'''Expression in mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John at 11:07, 3 July 2023

2023-07-03T11:07:30Z

← Older revision		Revision as of 13:07, 3 July 2023
Line 46:		Line 46:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|~~<span style="font-size:100%">~~'''Expression in primitive cell types'''</font>		!colspan="8"\|'''Expression in primitive cell types'''</font>
	\|-		\|- <span style="font-size:70%">
	! AML !! CMML !! B ALL !! ~~Burkitt~~ \|\| T ALL !! ETP ALL ~~<'''[[ETP ALL\|I]]'''>~~ !! ~~MPAL <'''[[~~MPAL~~\|I]]'''>~~ \|\| ~~Hgns~~ <~~'''[[Hgns\|I]]'''~~>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%

John at 13:32, 10 May 2023

2023-05-10T13:32:01Z

← Older revision		Revision as of 15:32, 10 May 2023
Line 61:		Line 61:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' Expression of CD22 is a feature of B-lineage commitment that is not essential for diagnosis, but strongly suggests B lineage. Aberrant expression is uncomon and should suggest the possibility of ~~bilineage disease~~ </span>		<span style="font-size:90%">'''Notes:''' Expression of CD22 is a feature of B-lineage commitment that is not essential for diagnosis, but strongly suggests B lineage. Aberrant expression is uncomon and should suggest the possibility of MPAL </span>

John at 13:31, 10 May 2023

2023-05-10T13:31:18Z

← Older revision		Revision as of 15:31, 10 May 2023
Line 61:		Line 61:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~xxxxx~~ </span>		<span style="font-size:90%">'''Notes:''' Expression of CD22 is a feature of B-lineage commitment that is not essential for diagnosis, but strongly suggests B lineage. Aberrant expression is uncomon and should suggest the possibility of bilineage disease </span>


Line 81:		Line 81:
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~xxxxx~~ </span>		<span style="font-size:90%">'''Notes:''' The level of expression may vary both between and within cases of mature B cell neoplasm, but expression tends to be lost by mature plasma cells </span>


Line 91:		Line 91:
	! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL		! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
	\|-		\|-
	\|style="width: 14.25%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~xxxxx~~ </span>		<span style="font-size:90%">'''Notes:''' Expression of CD22 is uncommon in mature T cell disorders </span>

	----		----

John at 08:27, 10 May 2023

2023-05-10T08:27:15Z

← Older revision		Revision as of 10:27, 10 May 2023
Line 70:		Line 70:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|-		\|-
	\|}		\|}

John at 08:23, 10 May 2023

2023-05-10T08:23:24Z

← Older revision		Revision as of 10:23, 10 May 2023
Line 51:		Line 51:
	\|-		\|-
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20~~#66e0ff ~~40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|~~? <5% 5-20%~~ 20-40~~% 40-80% 80-100~~%		\|style="width: 12.5%; background: #66e0ff; color:black"\|20-40%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

John at 08:16, 10 May 2023

2023-05-10T08:16:04Z

← Older revision		Revision as of 10:16, 10 May 2023
Line 50:		Line 50:
	! AML !! CMML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL <'''[[ETP ALL\|I]]'''> !! MPAL <'''[[MPAL\|I]]'''> \|\| Hgns <'''[[Hgns\|I]]'''>		! AML !! CMML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL <'''[[ETP ALL\|I]]'''> !! MPAL <'''[[MPAL\|I]]'''> \|\| Hgns <'''[[Hgns\|I]]'''>
	\|-		\|-
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%		\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%
	\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%		\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%

John at 08:14, 10 May 2023

2023-05-10T08:14:10Z

← Older revision		Revision as of 10:14, 10 May 2023
Line 22:		Line 22:
	<span style="color:navy">'''Diagnostic role'''</span>		<span style="color:navy">'''Diagnostic role'''</span>

	*Cytoplasmic expression of CD22 gives particular value in the detection of pro-B ALL where diagnosis requires expression at least two of: CD22 (membrane or cytoplasm), CD19 or CD79a. CD22 may not be uniformly expressed across a cell population with expression often being seen on only 60-90 of cells		*Cytoplasmic expression of CD22 gives particular value in the detection of pro-B ALL where diagnosis requires expression at least two of three markers: CD22 (membrane or cytoplasm), CD19 or CD79a. CD22 may not be uniformly expressed across a cell population with expression often being seen on only 60-90 of cells
	*in mature B cell neoplasms CD22 has relatively low expression in CLL, MCL and FL, but has high expression in HCL		*in mature B cell neoplasms CD22 has relatively low expression in CLL, MCL and FL, but has high expression in HCL

John at 08:13, 10 May 2023

2023-05-10T08:13:02Z

← Older revision		Revision as of 10:13, 10 May 2023
Line 6:		Line 6:

	:CD22 expression is largely restricted to B-lymphocytes		:CD22 expression is largely restricted to B-lymphocytes
	:The major value of CD22 lies in the identification of ALL based on high lineage-specificity and very early acquisition~~, first~~ in cytoplasm ~~then on~~ cell surface		:The major value of CD22 lies in the identification of ALL based on high lineage-specificity and very early acquisition in cytoplasm followed by cell surface expression

John at 20:17, 9 May 2023

2023-05-09T20:17:14Z

← Older revision		Revision as of 22:17, 9 May 2023
Line 16:		Line 16:
	<span style="color:navy">'''Normal expression and function'''</span>		<span style="color:navy">'''Normal expression and function'''</span>

	CD22 is a membrane adhesion receptor whose expression is mostly restricted to B lymphocytes where it is believed to be a negative regulator of activation. Expression is developmentally related - first appearing in cytoplasm of pro-B cells then on the surface in pre-B cells. CD22 is fully expressed by mature-B cells, but is lost during plasma cell differentiation. ~~Basophils express CD22.~~		CD22 is a membrane adhesion receptor whose expression is mostly restricted to B lymphocytes where it is believed to be a negative regulator of activation. Expression is developmentally related - first appearing in cytoplasm of pro-B cells then on the surface in pre-B cells. CD22 is fully expressed by mature-B cells, but is lost during plasma cell differentiation.


Line 22:		Line 22:
	<span style="color:navy">'''Diagnostic role'''</span>		<span style="color:navy">'''Diagnostic role'''</span>

	*~~xxxxx~~		*Cytoplasmic expression of CD22 gives particular value in the detection of pro-B ALL where diagnosis requires expression at least two of: CD22 (membrane or cytoplasm), CD19 or CD79a. CD22 may not be uniformly expressed across a cell population with expression often being seen on only 60-90 of cells
			*in mature B cell neoplasms CD22 has relatively low expression in CLL, MCL and FL, but has high expression in HCL





	<span style="color:navy">'''Other relevant information:'''</span>		<span style="color:navy">'''Other relevant information:'''</span>

	~~xxxxx~~		Basophils express CD22

← Older revision		Revision as of 10:27, 10 May 2023
Line 70:		Line 70:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|-		\|-
	\|}		\|}

← Older revision		Revision as of 10:23, 10 May 2023
Line 51:		Line 51:
	\|-		\|-
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20~~#66e0ff ~~40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|~~? <5% 5-20%~~ 20-40~~% 40-80% 80-100~~%		\|style="width: 12.5%; background: #66e0ff; color:black"\|20-40%
	\|style="width: 12.5%; background: ~~?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100~~#004466; color:white ~~black~~"\|~~? <5% 5-20% 20-40% 40-80%~~ 80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

← Older revision		Revision as of 10:16, 10 May 2023
Line 50:		Line 50:
	! AML !! CMML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL <'''[[ETP ALL\|I]]'''> !! MPAL <'''[[MPAL\|I]]'''> \|\| Hgns <'''[[Hgns\|I]]'''>		! AML !! CMML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL <'''[[ETP ALL\|I]]'''> !! MPAL <'''[[MPAL\|I]]'''> \|\| Hgns <'''[[Hgns\|I]]'''>
	\|-		\|-
	\|style="width: 12.5%; background: ~~?#FFE4E1 5~~#E6FAFF ~~20#66e0ff 40#00b8e6 80#006699;100#004466~~; color:~~white~~ black"\|? <5~~% 5-20% 20-40% 40-80% 80-100~~%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%		\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%
	\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%		\|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"\|? <5% 5-20% 20-40% 40-80% 80-100%